Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLA-B siRNA
- Development stage
- Preclinical
- Lead developer
- University of Nebraska Medical Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
HLA-B siRNA is a small interfering RNA designed to silence the expression of the Human Leukocyte Antigen B (HLA-B) heavy chain. HLA-B is a component of the HLA class I molecule, which typically presents antigens to cytotoxic T cells. In the context of pancreatic cancer research, HLA-B siRNA has been used as a laboratory tool to investigate the non-immunological roles of HLA class I molecules in tumor cell proliferation and migration. Studies have shown that silencing HLA-B can differentially affect the growth and movement of various pancreatic ductal adenocarcinoma cell lines, suggesting that HLA-B may contribute to the pathogenesis of certain cancers beyond its role in immune recognition.
- Other names
- siRNA specific for HLA-B heavy chainHLA-B heavy chain siRNA
02
Targets
HLA-B
Beyond the preview
Go deeper on HLA-B siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLA-B siRNA.